| abstract |
The present invention relates fusion proteins and their use in enzymatic treatment of Alzheimer's disease patients. Said fusion protein has the formula M-A, capable of degrading amyloid beta peptide at one or more cleavage sites in its amino acid sequence, wherein M is a protein componentthat prolongs the half-life of the fusion protein, and A is a protein component that cleaves the amyloid beta peptide. |